Innate Pharma (Nasdaq: IPHA) joins Leerink Partners Global Healthcare Conference 2026

Rhea-AI Filing Summary

Innate Pharma S.A. filed a report noting that its executive team will take part in the Leerink Partners Global Healthcare Conference 2026 in Miami from March 8–11. The company will host a fireside chat on March 9 at 3:40 PM ET, with a live webcast and replay available through the Investors section of its website.

The filing also highlights Innate Pharma’s focus on developing next-generation antibody-based immunotherapies for cancer, including IPH4502, lacutamab and monalizumab, and mentions ongoing collaborations with major partners such as AstraZeneca and Sanofi.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: Wednesday February 18, 2026

Commission File Number: 001-39084

Innate Pharma S.A.

(Translation of registrant's name into English)

Innate Pharma S.A.

117 Avenue de Luminy—BP 30191

13009 Marseille, France

+ 33 (0) 4 30 30 30

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]    Form 40-F [ ]

EXHIBIT INDEX

Exhibit Description

99.1 Press Release dated Wednesday February 18, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INNATE PHARMA S.A.

Date: Wednesday February 18, 2026    By:    /s/ JONATHAN DICKINSON     Name:    Jonathan Dickinson

Title:    Chief Executive Officer

EXHIBIT 99.1

Innate pharma to participate in the Leerink Partners Global Healthcare Conference

Marseille, France, February 18, 2026, 7:00 A.M. CET

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one investor meetings at the following conference:

Leerink Partners Global Healthcare Conference 2026

•    Dates: March 8–11, 2026

•    Location: Miami, Florida, United States

Fireside chat:

•    Date: March 9, 2026

•    Time: 3:40 PM ET / 20:40 CET

•    To enter the live webcast, please click here

The link to access the live webcast of the presentation will be available on the Events page of the Investors section of Innate Pharma’s website. A replay of the presentation will be available following the event.

About Innate Pharma:

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X. 

Information about Innate Pharma shares:

ISIN code: FR0010331421

Ticker code: Euronext: IPH Nasdaq: IPHA

LEI: 9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors:

For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority

(“AMF”), which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma’s website (www.innate-pharma.com), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors & Media Relations

Innate Pharma 

Stéphanie Cornen 

stephanie.cornen@innate-pharma.fr 

Investor Relations

investors@innate-pharma.fr 

Media

communication@innate-pharma.fr

FAQ

What did Innate Pharma (IPHA) announce in this 6-K filing?

Innate Pharma announced participation in the Leerink Partners Global Healthcare Conference 2026, including a fireside chat and one-on-one investor meetings. The company will webcast the March 9 presentation and provide a replay via the Investors section of its website.

When and where is Innate Pharma’s Leerink Partners conference presentation?

Innate Pharma’s fireside chat is scheduled for March 9, 2026, at 3:40 PM ET during the Leerink Partners Global Healthcare Conference in Miami, Florida. A live webcast and replay will be accessible through the company’s investor relations webpage.

How can investors watch Innate Pharma’s Leerink Partners fireside chat?

Investors can access a live webcast of Innate Pharma’s March 9, 2026 fireside chat via a link on the Events page in the Investors section of the company’s website. A replay of the presentation will be made available after the event concludes.

What kind of company is Innate Pharma (IPHA)?

Innate Pharma is a global, clinical-stage biotechnology company developing antibody-based immunotherapies for cancer patients. It focuses on next-generation antibody therapeutics and maintains collaborations with partners including AstraZeneca and Sanofi, as well as leading academic and research institutions in immuno-oncology.

Which key drug candidates does Innate Pharma highlight in this filing?

Innate Pharma highlights IPH4502, a Nectin-4 antibody-drug conjugate for solid tumors, lacutamab for cutaneous and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed with AstraZeneca for non-small cell lung cancer, reflecting its focus on high unmet medical need areas.

On which exchanges are Innate Pharma shares listed and under what tickers?

Innate Pharma shares are listed on Euronext Paris under the ticker IPH and on Nasdaq under the ticker IPHA. The company’s shares carry ISIN code FR0010331421 and are associated with LEI 9695002Y8420ZB8HJE29 in this disclosure.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 12.5 KB